NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844. Epub 2022 Feb 28.
Retrospective studies report that visualisation of the liver may be severely limited using ultrasound (US), potentially contributing to diminished sensitivity for detection of hepatocellular carcinoma (HCC) among patients with nonalcoholic fatty liver disease (NAFLD) and cirrhosis, but there are limited prospective data.
To compare liver visualisation scores prospectively for US and abbreviated hepatobiliary phase (HBP) magnetic resonance imaging (AMRI) in a cohort of participants with NAFLD cirrhosis and a clinical indication for HCC surveillance.
This prospective multicenter study included 54 consecutive participants (67% women) with NAFLD cirrhosis who underwent contemporaneous US as well as HBP-AMRI with gadoxetic acid. Primary outcome was the proportion of imaging examinations with severe limitations in liver visualisation (visualisation score C) compared head-to-head between US and AMRI.
The mean (± standard deviation) age was 63.3 years (±8.4) and body mass index was 32.0 kg/m (±6.0). Nineteen participants (35%) had severe visualisation limitations on US, compared with 10 (19%) with AMRI, p < 0.0001. Nine (17%) participants had <90% of the liver visualised on US, compared with only 1 (2%) participant with AMRI, p < 0.0001. Obesity was a strong and independent predictor for severe visualisation limitation on US (OR 5.1, CI 1.1-23.1, p = 0.03), after adjustment for age, sex and ethnicity.
More than one-third of participants with NAFLD cirrhosis had severe visualisation limitations on US for HCC screening, compared with one-sixth on AMRI. US adequacy should be reported in all clinical studies and when suboptimal then AMRI may be considered for HCC screening.
回顾性研究报告称,在非酒精性脂肪性肝病(NAFLD)和肝硬化患者中,超声(US)检查可能严重限制了肝脏的可视化,从而降低了对肝细胞癌(HCC)的检测敏感性,但前瞻性数据有限。
在有 NAFLD 肝硬化且有 HCC 监测临床指征的患者队列中,前瞻性比较 US 和缩短肝胆期(HBP)磁共振成像(MRI)的肝脏可视化评分。
这项前瞻性多中心研究纳入了 54 例连续的 NAFLD 肝硬化患者(67%为女性),他们同时接受了 US 和钆塞酸葡胺 HBP-MRI 检查。主要结局是比较 US 和 AMRI 检查肝脏可视化严重受限(可视化评分 C)的影像学检查比例。
患者的平均(±标准差)年龄为 63.3 岁(±8.4),体重指数为 32.0kg/m(±6.0)。19 例(35%)患者 US 检查存在严重的可视化限制,而 AMRI 检查中仅有 10 例(19%)存在严重的可视化限制,p<0.0001。9 例(17%)患者 US 检查中<90%的肝脏可以被可视化,而 AMRI 检查中只有 1 例(2%)患者存在这种情况,p<0.0001。肥胖是 US 检查严重可视化受限的强烈独立预测因素(OR 5.1,95%CI 1.1-23.1,p=0.03),调整年龄、性别和种族后仍有统计学意义。
与 AMRI 检查相比,超过三分之一的 NAFLD 肝硬化患者的 HCC 筛查 US 检查存在严重的可视化限制,而 AMRI 检查仅有六分之一存在严重的可视化限制。在所有临床研究中都应报告 US 的充分性,如果不理想,则可以考虑 AMRI 进行 HCC 筛查。